Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

  1. Argilés G, et al. Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). Annals of Oncology 2019; 30 (4 suppl): abstr O-026.
  2. Anderson R, et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist.2009;14:291–302.
  3. Arnault JP, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009;27:e59–e61.
  4. Autier J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144:886–892.
  5. Balagula Y, et al. Dermatologic toxicities of targeted anticancer therapies. J Support Oncol. 2010;8:149-161.
  6. Beech J, et al. Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol. 2018;14:2531-2541.
  7. Bekaii-Saab TS, et al. A. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(8):1070-1082.
  8. Beldner M, et al. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. The Oncologist. 2007;12:1178–1182.
  9. Belum VR, et al. Skin toxicity of targeted cancer agents: mechanisms and intervention. Future Oncol. 2013;9:1161-70.
  10. Belum VR, et al. Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol. 2015;26:2496-502.
  11. Bensadoun RJ, et al. Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel. Cancer Manag Res. 2013;5:401-8.
  12. Bjarnason GA, et al. The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. Eur J Cancer. 2019;108:69-77.
  13. Boers-Doets CB, et al. Oral Adverse Events Associated with Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review. Oncologist 2012; 17(1):135-144.
  14. Boers-Doets CB, et al. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol 2013; 9(12):1883-1892.
  15. Boers-Doets CB. The TARGET SYSTEM. Approach to assessment, grading, and management of dermatological & mucosal side effects of targeted anticancer therapies. ISBN 978-94-92070-00-5. 2014
  16. Breaker K, et al. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma Dermatol Surg. 2013;39:981–987.
  17. Brose MS, et al. Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer Treat Rev. 2018;66:64-73.
  18. Cabanillas ME and Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol. 2019;46(1):57-64.
  19. Califano R, et al. Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs. 2015;75:1335-48.
  20. Cignola S, et al. Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients. Eur J Oncol Nurs. 2016;20:133-9.
  21. Chan A, Tan EH. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer. 2011;19:1667-1674.
  22. Chanprapaph, K, et al. Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatology Research and Practice. 2014;2014:1-8.
  23. Claveau J, et al. Metastatic melanoma: optimizing outcomes by managing dermatologic toxicities associated with novel therapies. Skin Therapy Lett. 2014; 19: 1-4.
  24. De Wit M, et al. Prevention and management of adverse events related to regorafenib. Support Care Cancer. Support Care Cancer. 2014;22:837–846.
  25. Etienne G, et al. Imatinib mesylate and gray hair. N Engl J Med. 2002; 347:446.
  26. European Medicines Agency. Cabometyx (cabozantinib) Summary of Product Characteristics 2019.
  27. European Medicines Agency. Cometriq (cabozantinib) Summary of Product Characteristics 2019.
  28. Food and Drug Administration. Cabometyx (cabozantinib) Prescribing Information 2019.
  29. Food and Drug Administration. Cometriq (cabozantinib) Prescribing Information 2018.
  30. European Medicines Agency. Sprycel (dasatinib) Summary of Product Characteristics 2019.
  31. Food and Drug Administration. Sprycel (dasatinib) Prescribing Information 2018.
  32. European Medicines Agency. Glivec (imatinib) Summary of Product Characteristics 2019.
  33. Food and Drug Administration. Gleevec (imatinib) Prescribing Information 2018.
  34. European Medicines Agency. Kisplyx (lenvatinib) Summary of Product Characteristics 2019.
  35. European Medicines Agency. Lenvima (lenvatinib) Summary of Product Characteristics 2019.
  36. Food and Drug Administration. Lenvima (lenvatinib) Prescribing Information 2018.
  37. European Medicines Agency. Rydapt (midostaurin) Summary of Product Characteristics 2018.
  38. Food and Drug Administration. Rydapt (midostaurin) Prescribing Information 2018.
  39. European Medicines Agency. Votrient (pazopanib) Summary of Product Characteristics 2018.
  40. Food and Drug Administration. Votrient (pazopanib) Prescribing Information 2017.
  41. European Medicines Agency. Stivarga (regorafenib) Summary of Product Characteristics 2018.
  42. Food and Drug Administration. Stivarga (regorafenib) Prescribing Information 2019.
  43. European Medicines Agency. Nexavar (sorafenib) Summary of Product Characteristics 2018.
  44. Food and Drug Administration. Nexavar (sorafenib) Prescribing Information 2018.
  45. European Medicines Agency. Sutent (sunitinib) Summary of Product Characteristics 2019.
  46. Food and Drug Administration. Sutent (sunitinib) Prescribing Information 2019.
  47. European Medicines Agency. Caprelsa (vandetanib) Summary of Product Characteristics 2019.
  48. Food and Drug Administration. Caprelsa (vandetanib) Prescribing Information 2018.
  49. Gerendash BS and Creel PA. Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma. Onco Targets Ther. 2017;10:5053-5064.
  50. Giacchero D, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol. 2012;148:1418–1420.
  51. Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. The Oncologist. 2011;16:1508 –1519.
  52. Grande E, et al. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther. 2013; 30: 945-966.
  53. Grothey A, et al. Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. ASCO 2013; abstract 3637.
  54. Grothey A, et al. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014;19:669-80.
  55. Guztmer R, et al. Cutaneous side effects of new antitumor drugs: clinical features and management. Dtsch Arztebl Int. 2012;109:133–140.
  56. Hofheinz RD, et al. Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. Crit Rev Oncol Hematol 2017; 114:102-13
  57. Huang X, et al. Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther. 2009;2:215–219.
  58. Kollmannsberger C, et al. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist. 2011;16:543–553.
  59. Komatsu H, et al. Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: A qualitative study. Eur J Oncol Nurs. 2019;38:65-69.
  60. Krishnamoorthy SK, et al. Management of regorafenib-related toxicities: a review. Therap Adv Gastroenterol. 2015;8:285-97.
  61. Kudo T, et al. Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy. J Clin Oncol 2018;36(suppl 4S); abstr821.
  62. Lacouture ME & Melosky BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett. 2007;12:1-5.
  63. Lacouture ME, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase. Oncologist. 2008;13:1001-1011.
  64. Lacouture ME, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010;18:509-522.
  65. Lacouture ME, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28:1351-7.
  66. Lacouture ME, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079–1095.
  67. Lynch TJ Jr, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007; 12: 610-21.
  68. Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol. 2011;9(1):13-23.
  69. Manousaridis I, et al. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol. 2013;27:11–18.
  70. Maráz A, et al. Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma. BMC Cancer. 2018;18(1):296.
  71. McGuire DB, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:3165-3177.
  72. McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther. 2011;24:396–400.
  73. McLellan B, et al. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol. 2015;26:2017-26.
  74. Melosky B. Supportive care treatments for toxicities of anti-egfr and other targeted agents. Curr Oncol. 2012;19:S59-63.
  75. Oberholzer PA, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol. 2012;30: 316-321.
  76. Petrioli R et al. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy. Clin Colorectal Cancer. 2018;17(4):307-312.
  77. Potthoff K, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol. 2011;22:524–535.
  78. Robert C, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491-500.
  79. Robert C, et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009;60:299–305.
  80. Robert C, et al. Advances in the management of cutaneous toxicities of targeted therapies. Semin Oncol. 2012;39:227–240.
  81. Segaert S, et al. Skin toxicities of targeted therapies. Eur J Cancer. 2009;45:295-308.
  82. Shi VJ, et al. Cutaneous manifestations of nontargeted and targeted chemotherapies. Semin Oncol. 2016;43:419-25.
  83. Sinha R, et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. British Journal of Dermatology. 2012;167:987–994.
  84. Suchonwanit P and McMichael AJ. Alopecia in Association with Malignancy: A Review. Am J Clin Dermatol. 2018;19:853-865.
  85. Tang N, Ratner D. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer. Dermatol Surg. 2016;42 Suppl 1:S40-8.
  86. Walko CM, Grande C. Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective. Semin Oncol. 2014;41:S17–S28.
  87. Wood LS, et al. Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors Commun Oncol.2010;7:23–29.
  88. Widakowich C, et al. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist. 2007;12;1443-1455.
  89. Worthington HV, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2011 Apr 13;(4): CD00097.
  90. Wollenberg A, et al. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol. 2008; 17: 790-792.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings